Clinigen Group (CLIN)

 

CLIN Share PerformanceMore

52 week high793.5 10/10/16
52 week low492.8 16/06/16
52 week change 25.8 (3.72%)
4 week volume8,069,747 13/11/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Clinigen collaborates with Eisai in South Africa

Clinigen has announced a collaboration with Eisai which provides women in South Africa with access to eribulin for adv...

Clinigen collaborates with Eisai in South Africa

Director Deals - Clinigen Group (CLIN)

John Bacon, Non Executive Director, sold 200,000 shares in the company on the 11th November 2016 at a price of 717.00p. T...

Director/PDMR Shareholding

RNS Number: 0896P Clinigen Group plc 14 November 2016 14 November 2016 Director's Share Dealing Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services group, announces that it was notified on 11 November 2016 that the following transaction took place on 11 November 2016. John Bacon, Non-Executive Director, sold 200...

Clinigen resolutions passed at AGM

Clinigen Group has confirmed that all resolutions proposed at its annual general meeting today were passed. At 1:46pm: (LO...

Result of AGM

RNS Number: 9095O Clinigen Group plc 11 November 2016 11 November 2016 Result of AGM Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, announces that at the Annual General Meeting, held today, all resolutions were passed. The slides from the presentation given by the Group will be made available on C...

Clinigen says FY trading in-line

Clinigen said trading for the current financial year remains in line with the board's expectations. "The year to 30 June 2016...

AGM Statement

RNS Number: 9093O Clinigen Group plc 11 November 2016 11 November 2016 AGM statement Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, is holding its Annual General Meeting ("AGM") at 10.00am today. At the AGM, Peter Allen, Clinigen's Chairman will say: "The year to 30 June 2016 marked the compl...

Fundamental DataMore

P/E ratio60.399
EPS11.9
Dividend yield0.557 %

Equity Research (CLIN)

edison investment research
Clinigen Group Plc
01/03/2016
Edison Investment Research is terminating coverage on Clinigen Group (CLIN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be...
edison investment research
Clinigen Group Plc
25/01/2016
Clinigen’s H116 trading statement suggests its business is performing to plan, taking into account some revenue deferrals to H2. The integration of Idis and Link, which we expect to boost its...
edison investment research
Clinigen Group Plc
13/10/2015
Clinigen’s FY15 results demonstrated strong underlying fundamentals, with earnings and net debt better than our forecasts. The integration of Idis and the purchase of Link further its strategy as the...

Latest discussion posts More

  • Re: Well done Clinigen

    Just wished had topped up the days after Brexit! Like you said pharmaspecialist, debt down is always great to see, and the integration of the purchased businesses is being ...
    20-Jul-2016
    bushwhacker
  • Well done Clinigen

    Excellent results out today and I think justify the 11% share price increase at the time of writing. The results have also been achieved whilst lowering debt so they are real. ...
    20-Jul-2016
    pharmaspecialist
  • Results

    Looking forward to Wednesday's results.
    18-Jul-2016
    bushwhacker

Users' HoldingsMore

Users who hold Clinigen Group also hold..
GLAXOSMITHKLINE22%
BP18%
TELFORD HOMES17%
RDS 'B'17%
NATIONAL GRID16%

Codes & Symbols

ISINGB00B89J2419
SymbolsCLIN, LSE:CLIN, CLIN.L, CLIN:LN, LON:CLIN, XLON:CLIN